These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Role of radiotherapy of lung cancer].
    Author: Mardynskiĭ IuS, Zolotkov AG, Kudriavtsev DV.
    Journal: Vopr Onkol; 2006; 52(5):499-504. PubMed ID: 17168355.
    Abstract:
    Data on the 3-year end results of radiotherapy of inoperable localized nonsmall-cell lung cancer (286) and 5-year (98)--for chemoradiotherapy are compared. Three-year survival after hyperfractionated radiotherapy was 23.7% as compared with 11.3% when standard procedures were used. Five-year survival after hyperfractionated radiotherapy using dose escalation, induction consolidation chemotherapy with iphosphamide, etoposide, cisplatin or carboplatin rose from 3.8 to 24%, while patients were discharged 2-3 weeks earlier.
    [Abstract] [Full Text] [Related] [New Search]